Initial Beneficial Ownership · 3
Faeth Therapeutics, Inc.
FTHNASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
form3-09152026_080900.xml
Filing details
- Report period
- 2026-09-11
- Issuer
- Faeth Therapeutics, Inc.
- Issuer CIK
- 0001829802
- Trading symbol
- FTH
Reporting owner 1
- Name
- Vousden Karen H
- Reporting owner CIK
- 0001723884
- Relationship
- Director
- Address
- C/O FAETH THERAPEUTICS, INC., 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Stock | 42,631 | D |
Table key
- D
- Direct
Remarks
Exhibit 24 - Power of Attorney
Signature 1
- Signed
- /s/ Josiah Craver, Attorney-in-Fact
- Date
- 2026-09-15
Filed exhibits
- EX-24 ↗ex24-09152026_080910.htm
Company context
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph. D., together with scientific founders Lewis Cantley, Ph. D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph. D.; Scott Lowe, Ph. D.; and Greg Hannon, Ph. D. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.